Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Shibani Nicum(London Cancer), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Lucy Boyle(University of Oxford), Patrick Julier, Anna Schuh(University of Oxford), Susan Dutton(Oxford Centre for Diabetes, Endocrinology and Metabolism), Sarah Pearson(University of Oxford), Claire Brooks(Cancer Research UK Technology), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Rachel A Midgley(University of Oxford), Stanley B. Kaye(Royal Marsden Hospital), Charlie Gourley(Edinburgh Cancer Research), Rose Wharton
Cited by 1
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k